UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053068
Receipt number R000060555
Scientific Title Study of the utility of a new community cancer salon (Gan-Labo) using a living lab.
Date of disclosure of the study information 2023/12/12
Last modified on 2023/12/12 12:26:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of the utility of a new community cancer salon (Gan-Labo) using a living lab.

Acronym

Utility of a New Community Cancer Salon'Gan-Labo'

Scientific Title

Study of the utility of a new community cancer salon (Gan-Labo) using a living lab.

Scientific Title:Acronym

Utility of a New Community Cancer Salon'Gan-Labo'

Region

Japan


Condition

Condition

Breast cancer

Classification by specialty

Nursing

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

This study will examine the utility of a cancer lab that incorporates a cancer cafe, cancer salon, biometric measurements, and living lab approach, as it may contribute to maintaining and improving the quality of life of cancer survivors. The purpose of the study is also to examine the effects of physical and mental changes in gait, body balance, body composition, etc., and their influence on QOL by providing a baseline of physical and activity measurements such as gait, body balance, body composition, etc., and psychological checkups before the start of the cancer lab, as well as learning opportunities about exercise, nutrition, relaxation, and the latest information on breast cancer treatment. The purpose of this study is to examine the impact of these changes on quality of life.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

WHO-QOL26score

Key secondary outcomes

1. Questionnaire on the usefulness of the cancer lab
2. Anthropometric data: body composition and muscle mass, brachial circumference, grip strength, blood pressure, heart rate, finger pulse wave, height.
3.Activity measurement data: gait measurement (walking posture, walking speed), number of steps, activity level, standing balance measurement
4.Facial expression measurement data: facial images (44 facial muscle movements)
5.Subjective questionnaire: free description of pain/symptoms/feelings, bowel movements, sleep, appetite, fatigue, mood, exercise habits, history of falls, and any inconvenience in life, etc.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Behavior,custom

Interventions/Control_1

Four-month participation in a Gan-Labo

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

79 years-old >=

Gender

Male and Female

Key inclusion criteria

Must be a first-time breast cancer survivor between the ages of 20 and 79 years old who attends Niigata Breast Clinic in Japan.
Must be judged by the attending physician to have completed treatment and to be in stable condition (including those undergoing hormone therapy).
Must be willing to participate in the Cancer Lab once a month for at least 4 consecutive months for at least 1 year.

Key exclusion criteria

Patients with recurrent or local recurrence.
Patients with bilateral breast cancer.
Patients scheduled for breast reconstruction.
Patients undergoing molecular targeted therapy.
Participants who fail to participate in the study for more than 4 months will be considered as dropouts. Participants who fail to participate for more than 4 months will be considered to have dropped out of the study. In addition, those who failed to complete or had many missing items on the three questionnaires or those who left before or during the cancer lab and were unable to complete the questionnaires will also be considered as dropouts. Data from individuals who are cognitively impaired and unable to complete the questionnaires on their own will also be excluded.

Target sample size

120


Research contact person

Name of lead principal investigator

1st name Sayuri
Middle name
Last name Sakai

Organization

Niigata University

Division name

Graduate school of health sciences

Zip code

9518518

Address

46 Asahimachi dori2, Chuo-ku, Niigata city, Niigata Prefecture

TEL

+81252270941

Email

sakai@clg.niigata-u.ac.jp


Public contact

Name of contact person

1st name Sayuri
Middle name
Last name Sakai

Organization

Niigata University

Division name

Graduate school of health sciences

Zip code

9518518

Address

746 Asahimachi dori2, Chuo-ku, Niigata city, Niigata Prefecture

TEL

+81252270941

Homepage URL


Email

sakai@clg.niigata-u.ac.jp


Sponsor or person

Institute

Niigata University

Institute

Department

Personal name



Funding Source

Organization

Japan society the promotion of science, Grants-in-Aid for Scientific Research

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Niigata University

Address

757 Ichibancho, Asahimachi-dori, Chuo Ward, Niigata City 951-8510

Tel

+8525-227-2625

Email

ethics@adm.niigata-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 12 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2023 Year 12 Month 12 Day

Date of IRB

2023 Year 12 Month 01 Day

Anticipated trial start date

2023 Year 12 Month 12 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 12 Month 12 Day

Last modified on

2023 Year 12 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060555


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name